Malabaricone B, a naturally occurring plant phenolic, is an orally active α-glucosidase inhibitor with an IC 50 of 63.7 µM. Malabaricone B has anticancer, antimicrobial, anti-oxidation and antidiabetic activities . In Vitro Malabaricone B shows selective toxicity to human lung cancer (A549), malignant melanoma (A375) and T cell leukemia (Jurkat) cell lines, without showing toxicity to human normal intestinal (INT407), human kidney (HEK293) and lung fibroblast (WI-38) cells. Among the chosen cancer cell lines, Malabaricone B shows maximum cytotoxicity to the A549 cells (IC 50 = 8.1 μM), which is significantly better than that of curcumin (IC 50 = 26.7 μM). The Malabaricone B-induced apoptosis is mediated by an increase in the intracellular reactive oxygen species (ROS). Malabaricone B (2.5, 5, 10 and 20 µM) increases the BAX level while simultaneously decreasing the BCL-2 and BCL-XL levels in the A549 cells, triggering the mitochondrial apoptotic pathway as revealed from the release of cytochrome c, and the activation of caspase-9 and caspase-3. Malabaricone B exhibits a good level of antimicrobial activity when tested against avariety of microorganisms, including Staphylococcus aureus and Candida albicans. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Malabaricone B (100 mg/kg; p.o; alternate day, 23 days) inhibits lung tumor (xenograft) growth in SCID mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid